Free tool
FAERS Monitor: Baxdela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208611 or its brand name (Baxdela, Delafloxacin Meglumine). Reports on generic versions are filed under their own applications.
Reports
242
Serious
67
28% of reports
Hospitalization
21
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea76
- off label use28
- nausea19
- decreased appetite14
- rash13
- malaise12
- arthralgia10
- drug effective for unapproved indication10
- product use in unapproved indication10
- tremor10
- hypertension9
- pallor9
- presyncope9
- autonomic nervous system imbalance8
- drug ineffective7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 64 |
| 2019 | 110 |
| 2020 | 31 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 13 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,917 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| autonomic nervous system imbalanceSignal | 8 | 238.7 | 120.6 | 1,659 |
| presyncopeSignal | 9 | 32.2 | 16.9 | 242 |
| drug effective for unapproved indicationSignal | 10 | 29.7 | 16.2 | 249 |
| pallorSignal | 9 | 28.8 | 15.1 | 214 |
| diarrhoeaSignal | 76 | 10.2 | 8.5 | 644 |
| decreased appetiteSignal | 14 | 5.2 | 3.2 | 44 |
| tremorSignal | 10 | 5.2 | 2.9 | 30 |
| hypertensionSignal | 9 | 3.7 | 1.9 | 15 |
| product use in unapproved indicationSignal | 10 | 3.5 | 1.9 | 16 |
| off label useSignal | 28 | 2.8 | 2.0 | 31 |
| rashSignal | 13 | 2.6 | 1.5 | 11 |
| malaiseSignal | 12 | 2.4 | 1.4 | 8 |
| arthralgiaSignal | 10 | 2.1 | 1.1 | 5 |
| nauseaSignal | 19 | 2.1 | 1.4 | 10 |
| drug ineffective | 7 | 0.5 | 0.2 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.